1. COVID-19 and Atrial Fibrillation in Older Patients: Does Oral Anticoagulant Therapy Provide a Survival Benefit?-An Insight from the GeroCovid Registry.
- Author
-
Fumagalli S, Trevisan C, Del Signore S, Pelagalli G, Volpato S, Gareri P, Mossello E, Malara A, Monzani F, Coin A, Bellelli G, Zia G, and Antonelli Incalzi R
- Subjects
- Administration, Oral, Aged, Aged, 80 and over, Anticoagulants administration & dosage, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Atrial Fibrillation mortality, COVID-19 mortality, Female, Hospital Mortality, Humans, Italy epidemiology, Logistic Models, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Prevalence, Registries, Retrospective Studies, Risk Factors, COVID-19 Drug Treatment, Atrial Fibrillation complications, COVID-19 complications, SARS-CoV-2
- Abstract
Introduction: Atrial fibrillation (AF), the most frequent arrhythmia of older patients, associates with serious thromboembolic complications and high mortality. Coronavirus disease 2019 (COVID-19) severely affects aged subjects, determining an important prothrombotic status. The aim of this study was to evaluate mortality-related factors in older AF patients with COVID-19., Methods: Between March and June 2020, we enrolled ≥60 year-old in-hospital COVID-19 patients ( n = 806) in GeroCovid, a multicenter observational study promoted by the Italian Society of Gerontology and Geriatric Medicine., Results: The prevalence of AF was 21.8%. In-hospital mortality was higher in the AF group (36.9 vs. 27.5%, p = 0.015). At admission, 51.7, 10.2, and 38.1% of AF cases were taking, respectively, oral anticoagulants (OACs), antiplatelet agents, and no antithrombotic therapy. During hospitalization, 51% patients switched to low-molecular-weight heparins. AF patients who survived were younger (81 ± 8 vs. 84 ± 7 years; p = 0.002) and had a lower CHA
2 DS2 -VASc score (3.9 ± 1.6 vs. 4.4 ± 1.3; p = 0.02) than those who died. OAC use before (63.1 vs. 32.3%; p < 0.001) and during hospitalization (34.0 vs. 12.7%; p = 0.002) was higher among survivors. At multivariable analysis, lower age, higher self-sufficiency, less severe initial COVID-19 presentation, and the use of vitamin K antagonists (odds ratio [OR] = 0.16, 95% confidence interval [CI]: 0.03-0.84) or direct OACs (OR = 0.22, 95% CI: 0.08-0.56) at admission, or the persistence of OAC during hospitalization (OR = 0.05, 95% CI: 0.01-0.24), were associated with a lower chance of in-hospital death., Conclusion: AF is a prevalent and severe condition in older COVID-19 patients. Advanced age, dependency, and relevant clinical manifestations of disease characterized a worse prognosis. Preadmission and in-hospital anticoagulant therapies were positively associated with survival., Competing Interests: None declared., (Thieme. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF